MedTrace Logo

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

NCT02159469 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-02-07

Study results available
· View outcomes & findings →

Summary

Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector

Conditions

  • Hypogonadism

Interventions

COMBINATION_PRODUCT

Testosterone enanthate auto-injector

Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Jed Kaminetsky, MD · Manhattan Medical Research Practice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-02-28
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159469 on ClinicalTrials.gov